search
Back to results

RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis (PRO-ESTER)

Primary Purpose

Obesity, Overweight

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Inulin acetate ester
Inulin propionate ester
Inulin butyrate ester
Sponsored by
Scottish Universities Environmental Research Centre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Obesity, Weight maintenance, Appetite, Energy intake, Dietary fibre, Short-chain fatty acids, Fermentation, Overweight

Eligibility Criteria

21 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Male and Female
  • Healthy
  • Overweight (BMI 25-40 kg/m2)

Exclusion Criteria:

  • Weight change of > 3kg in the preceding 2 months
  • Current smokers
  • Substance abuse
  • Excess alcohol intake
  • Diabetes
  • Cardiovascular disease
  • Cancer
  • Gastrointestinal disease
  • Kidney disease
  • Liver disease
  • Pancreatitis
  • Use of any medication except contraceptive pill
  • Peri-menopausal
  • Pregnancy
  • Breastfeeding

Sites / Locations

  • Glasgow Clinical Research Facility

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Inulin acetate ester

Inulin propionate ester

Inulin butyrate ester

Arm Description

Inulin acetate ester, 10g/day for 30 days

Inulin propionate ester, 10g/day for 30 days

Inulin butyrate ester, 10g/day for 30 days

Outcomes

Primary Outcome Measures

Energy intake at ad libitum meal
Energy intake is measured at an ad libitum meal

Secondary Outcome Measures

Subjective appetite sensations
Appetite is rated on 100 mm visual analogue scales
Plasma glucose and insulin
Oral glucose tolerance test: Fasting and 2h glucose and insulin concentrations following consumption of solution providing 75g glucose

Full Information

First Posted
May 19, 2015
Last Updated
April 27, 2016
Sponsor
Scottish Universities Environmental Research Centre
Collaborators
NHS Greater Clyde and Glasgow, University of Glasgow
search

1. Study Identification

Unique Protocol Identification Number
NCT02451189
Brief Title
RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis
Acronym
PRO-ESTER
Study Type
Interventional

2. Study Status

Record Verification Date
April 2016
Overall Recruitment Status
Completed
Study Start Date
January 2015 (undefined)
Primary Completion Date
April 2016 (Actual)
Study Completion Date
April 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Scottish Universities Environmental Research Centre
Collaborators
NHS Greater Clyde and Glasgow, University of Glasgow

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Obesity, with its associated co-morbidities, is a major public health challenge. It is estimated that by 2050, 60% of men and 50% of women will be clinically obese. Obesity is associated with increased risk of developing diabetes, cardiovascular disease, and certain cancers. The increasing epidemic of obesity has necessitated the study of the complex mechanisms underlying energy homeostasis. Food intake, energy balance and body weight are tightly regulated by the hypothalamus, brainstem and reward circuits, on the basis both of cognitive inputs and of diverse humoral and neuronal signals of nutritional status. Several gut hormones, including glucagon-like peptide-1 (GLP-1) and peptide YY3-36 (PYY), have been shown to play an important role in regulating short-term food intake. Peripheral administration of PYY or GLP-1 enhances satiety and reduces food intake in animals and man. PYY, GLP-1 along with a host of other hormones are produced by the gut in response to nutrient availability in different regions of the gut and provide an exquisite mechanism of nutrient sensing in response to dietary intake. These hormones therefore represent potential targets in the development of novel anti-obesity treatments. A novel and attractive strategy to induce appetite regulation is the enrichment of foods with components that stimulate the release of GLP-1 and PYY. The short chain fatty acids (SCFA) produced by microbial fermentation of dietary fibre in the colon have been shown to stimulate the release of PYY and GLP-1 from rodent enteroendocrine L cells, via stimulation of the G-protein coupled free fatty acid receptors (FFAR) on colonic L cells. However, it is not known whether the three SCFA, acetate, butyrate and propionate, differentially affect appetite and glucose control. The aim of this study is to compare the effects of increased colonic delivery of acetate, butyrate and propionate on appetite and glucose control in overweight men in a randomised crossover study.
Detailed Description
The role of SCFA in appetite regulation: SCFA have been shown to stimulate PYY and GLP-1 production in animal models and dietary fibre, of which SCFA are the major end products, induce appetite regulation in humans. However the evidence underpinning which dietary fibres induce appetite regulation in humans is very weak because of the difficulty in controlling studies with very high fibre intake. In a recent project funded under the BBSRC DRINC initiative (BB/H004815/1), the investigators have the first direct evidence that SCFA can directly regulate appetite in humans. Prior to this study, in order to achieve production of SCFA to a level, which is high enough to induce appetite-regulating effects, very large amounts of dietary fibre (>25 g/d and up to 40 g/d) are required, and compliance with high fibre diets is poor due to gastrointestinal side effects. Furthermore, supplementing diets with mixed high fibre does not predictably or reliably increase colonic SCFA production or circulating levels of SCFA in all human populations because of the variability in gut microbial activity. Finally, orally administered SCFAs are not palatable and are rapidly absorbed in the small intestine where L cells are sparse. In our studies to date we have focussed on the SCFA propionate because it has the highest affinity for the receptors and is an end product of metabolism in the microbiota and therefore seems the obvious target to manipulate to investigate the effects of SCFA on appetite regulation. To overcome the unpalatably high levels of fermentable dietary fibre needed to significantly increase colonic propionate levels, and the unpredictability in the production of the resulting SCFAs, the investigators have developed and tested a novel delivery system targeting the release of gram quantities of propionate in the proximal colon. It is estimated that the delivery system may lead to a 2-8 fold increase in colonic propionate, a level very difficult to achieve through feeding a mixed fermentable fibre diet. This level of propionate production might have been observed in ancestral diets and in parts of rural Africa where dietary fibre intake is very high. Previous work, conducted by the investigators, has also demonstrated that delivery system increases plasma propionate levels, reduces food intake in acute studies of appetite, and in a longer term study (24 weeks), positive effects on food intake, body composition, glucose homeostasis, circulating lipids, cholesterol and liver function, liver and visceral fat and weight management were observed. However, at present it is not known if acetate, propionate and butyrate exert similar effects on appetite and glucose metabolism. Therefore in this study we wish to compare the the effects of targeted delivery of acetate, propionate and butyrate to the proximal colon on appetite and glucose homeostasis in overweight men.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Overweight
Keywords
Obesity, Weight maintenance, Appetite, Energy intake, Dietary fibre, Short-chain fatty acids, Fermentation, Overweight

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
23 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Inulin acetate ester
Arm Type
Experimental
Arm Description
Inulin acetate ester, 10g/day for 30 days
Arm Title
Inulin propionate ester
Arm Type
Experimental
Arm Description
Inulin propionate ester, 10g/day for 30 days
Arm Title
Inulin butyrate ester
Arm Type
Experimental
Arm Description
Inulin butyrate ester, 10g/day for 30 days
Intervention Type
Dietary Supplement
Intervention Name(s)
Inulin acetate ester
Intervention Description
Inulin acetate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and oral glucose tolerance test (OGTT) on day 30.
Intervention Type
Dietary Supplement
Intervention Name(s)
Inulin propionate ester
Intervention Description
Inulin propionate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
Intervention Type
Dietary Supplement
Intervention Name(s)
Inulin butyrate ester
Intervention Description
Inulin butyrate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
Primary Outcome Measure Information:
Title
Energy intake at ad libitum meal
Description
Energy intake is measured at an ad libitum meal
Time Frame
8 hours
Secondary Outcome Measure Information:
Title
Subjective appetite sensations
Description
Appetite is rated on 100 mm visual analogue scales
Time Frame
8 hours
Title
Plasma glucose and insulin
Description
Oral glucose tolerance test: Fasting and 2h glucose and insulin concentrations following consumption of solution providing 75g glucose
Time Frame
2 hours
Other Pre-specified Outcome Measures:
Title
Intestinal bacteria composition
Description
Faecal samples will be collected to assess the impact of the NDC esters on gut bacteria composition
Time Frame
24 hours
Title
Lipids
Description
Serum triglycerides and cholesterol concentrations will be determined
Time Frame
8 hours
Title
Appetite regulating gut hormones
Description
Fasting and postprandial gut hormone concentrations will be measured
Time Frame
8 hours
Title
Liver function test
Time Frame
1hour

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male and Female Healthy Overweight (BMI 25-40 kg/m2) Exclusion Criteria: Weight change of > 3kg in the preceding 2 months Current smokers Substance abuse Excess alcohol intake Diabetes Cardiovascular disease Cancer Gastrointestinal disease Kidney disease Liver disease Pancreatitis Use of any medication except contraceptive pill Peri-menopausal Pregnancy Breastfeeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Douglas Morrison, PhD
Organizational Affiliation
Scottish Universitites Environmental Research Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Glasgow Clinical Research Facility
City
Glasgow
State/Province
Lanarkshire
ZIP/Postal Code
G4 0SF
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis

We'll reach out to this number within 24 hrs